Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Labopharm once-daily tramadol "approvable"

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Labopharm may still have a chance to get its once-daily tramadol product on the market by year end if it resopnds quickly to a Sept. 28 "approvable" letter and receives a Class 1 designation for its response. The firm did not disclose the issues cited in FDA's letter, but said no additional data will be needed to address them; the NDA was submitted Nov. 28, 2005 (1Pharmaceutical Approvals Monthly December 2005, In Brief)...

You may also be interested in...



Labopharm once-daily tramadol goal date is June 19

The user fee goal for Labopharm's once-daily tramadol formulation is June 19, the Canadian firm says Jan. 16. The new goal date reflects Labopharm's December complete response to a Sept. 28, 2006, "approvable" letter (1Pharmaceutical Approvals Monthly October 2006, In Brief). The response contains additional analyses of existing data but no new data, the firm said. Labopharm is also appealing the letter. The June 19 user fee goal could put Labopharm behind Cipher's competing extended-release tramadol NDA, which has a May 1 action date...

Alnylam Shows Efficacy, Safety With Lumasiran In Vulnerable Pediatric Patients

The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.

Bayer Gives Consumer Health A Star, But Plans $1.76Bn In Annual Overall Cost Reductions

Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel